Adipogen/Etoposide/AG-CR1-3572-M025/25 mg
商品编号：
AG-CR1-3572-M025
品牌：
Adipogen Inc
市场价：
¥600.00
美元价：
360.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | VP-16-213;NSC141540 |
| ProductType | Chemical |
| Properties | |
| Formula | C29H32O13 |
| MW | 588.6 |
| MerckIndex | 14:3886 |
| CAS | 33419-42-0 |
| RTECS | KC0190000 |
| Source/HostChemicals | Semisyntheticderivativeofpodophyllotoxin. |
| PurityChemicals | ≥98%(HPLC) |
| Appearance | Whitetooff-whitepowder. |
| Solubility | SolubleinDMSO,ethanol,methanolordimethylformamide. |
| InChiKey | VJJPUSNTGOMMGY-MRVIYFEKSA-N |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +20°C |
| LongTermStorage | +20°C |
| HandlingAdvice | Protectfromlightandmoisture. |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat+20°C. StoresolutionsinDMSOat4°C. Afterreconstitution,preparealiquotsandstoreat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- Potentanti-cancercompound.Inducesapoptosisinnormalandtumorcelllines[1,5].
- DNATopoisomeraseIIactivityinhibitor.IncreasesTopoII-mediatedDNAbreakageprimarilybyinhibitingtheabilityoftheenzymetoreligatecleavednucleicacidmolecules.DoesnotleadtoimmediateblockofDNSsynthesis,inducesaprogressiveinhibitionofDNAreplication[2,4,6].
- p53activator[3].
- BlocksthecellcyclebetweentheendoftheSphaseandtheearlyG2phase[2,8].
- OncoproteinMdm2synthesisinhibitor[7].
- Apoptosisinducerthroughthecytochromec/Apaf-1/caspase-9pathwayandtheFas-mediateddeathsignalingpathway[9,10].
- Cellcyclecheckpointactivator.Affectsgeneexpressionatdifferentlevels(chromatinremodeling,transcriptionandalternativesplicing)[11,14,15].
- Chemotherapeuticcompoundusedincancers[12,13].
- Usedinconditioningregimenpriortoabonemarroworbloodstemcelltransplantation[16].
- Highlyeffectiveinmobilizingstemcells[17]
ProductReferences
- ThepodophyllotoxinderivativesVP16-213andVM26:B.F.Issell;CancerChemother.Pharmacol.7,73(1982)
- Topoisomerase-specificdrugsensitivityinrelationtocellcycleprogression:K.C.Chow&W.E.Ross;Mol.Cell.Biol.7,3119(1987)
- IncreasesinsequencespecificDNAbindingbyp53followingtreatmentwithchemotherapeuticandDNAdamagingagents:R.B.Tishler,etal.;CancerRes.53,2212(1993)
- TopoisomeraseII-etoposideinteractionsdirecttheformationofdrug-inducedenzyme-DNAcleavagecomplexes:D.A.Burden,etal.;J.Biol.Chem.271,29238(1996)
- Celldeathinducedbytopoisomerase-targeteddrugs:morequestionsthananswers:S.H.Kaufmann;Biochim.Biophys.Acta1400,195(1998)(Review)
- Etoposide:fourdecadesofdevelopmentofatopoisomeraseIIinhibitor:K.R.Hande;Eur.J.Cancer34,1514(1998)(Review)
- Differentialregulationofp21waf-1/cip-1andMdm2byetoposide:etoposideinhibitsthep53-Mdm2autoregulatoryfeedbackloop:E.L.Arriola,etal.;Oncogene18,1081(1999)
- Earlycaspaseactivationinleukemiccellssubjecttoetoposide-inducedG2-Marrest:evidenceofcommitmenttoapoptosisratherthanmitoticcelldeath:R.J.Sleiman&B.W.Stewart;Clin.CancerRes.6,3756(2000)
- Orderingofceramideformation,caspaseactivation,andBax/Bcl-2expressionduringetoposide-inducedapoptosisinC6gliomacells:M.Sawada,etal.;CellDeathDiffer.7,761(2000)
- Distinctpathwaysforstimulationofcytochromecreleasebyetoposide:J.D.Robertson,etal.;J.Biol.Chem.275,32438(2000)
- DeacetylaseactivityassociateswithtopoisomeraseIIandisnecessaryforetoposide-inducedapoptosis:C.A.Johnson,etal.;J.Biol.Chem.276,4539(2001)
- Etoposide:discoveryandmedicinalchemistry:P.Meresse,etal.;Curr.Med.Chem.11,2443(2004)(Review)
- Etoposide,topoisomeraseIIandcancer:E.L.Baldwin&N.Osheroff;Curr.Med.Chem.AnticancerAgents5,363(2005)(Review)
- ThedispersalofreplicationproteinsafterEtoposidetreatmentrequiresthecooperationofNbs1withtheataxiatelangiectasiaRad3-related/Chk1pathway:R.Rossi,etal.;CancerRes.66,1675(2006)
- Cellularresponsetoetoposidetreatment:A.Montecucco&G.Biamonti;CancerLett.252,9(2007)(Review)
- ChemomobilizationwithEtoposideisHighlyEffectiveinPatientswithMultipleMyelomaandOvercomestheEffectsofAgeandPriorTherapy:W.A.Wood,etal.;Biol.BloodMarrow.Transplant.17,141(2011)
- Theagingeffectofchemotherapyonculturedhumanmesenchymalstemcells.S.Buttiglieri,etal.;Exp.Hematol.39,1171(2011)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
